Forsøksdyr: CD100-based treatments in PSC mouse models

Godkjenningsdato 05.01.2018

Godkjenningsperiode 01.02.2018-01.02.2021

Our previous investigations have found CD100 deficency and a missense mutation exacerbate disease process in mouse sclerosing cholangitis models. Now we would like to survey some CD100-based treatments in these gene modified mice, which might be further applied to primary sclerosing cholangitis (PSC) patients.

Soluble CD100 will be supplied to animals via tail vein injection. Considering CD100 is also expressed on immune cells, especially T cells, CD100 gene modified mice will receive bone marrow transplantation or adoptive T cell transfer from wild type donors. Sclerosing cholangitis will be induced in these treated animals by 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diet feeding. We would like to check if mice are benefit from the treatment or not.

Mice with DDC diet suffer biliary disease by showing yellow skin and loss of body weight. But it is less stressful comparing to other models like bile duct ligation surgeries. All mice will be carefully traced and scored during the whole procedure. Numbers of mice are set to minimum by power calculation.